N-(biphenyl-4-yl)-N-(4′-broMobiphenyl-4-yl)-9,9-diMethyl-9H-fluoren-2-amine

We are N-(biphenyl-4-yl)-N-(4′-broMobiphenyl-4-yl)-9,9-diMethyl-9H-fluoren-2-amine CAS:1268621-99-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:N-(biphenyl-4-yl)-N-(4'-broMobiphenyl-4-yl)-9,9-diMethyl-9H-fluoren-2-amine
CAS.NO:1268621-99-3
Synonyms:FBBPA
N-(biphenyl-4-yl)-N-(4'-broMobiphenyl-4-yl)-9,9-diMethyl-9H-fluoren-2-amine
9H-Fluoren-2-amine, N-[1,1'-biphenyl]-4-yl-N-(4'-bromo[1,1'-biphenyl]-4-yl)-9,9-dimethyl-
Molecular Formula:C39H30BrN
Molecular Weight:592.5662
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates

N-(biphenyl-4-yl)-N-(4'-broMobiphenyl-4-yl)-9,9-diMethyl-9H-fluoren-2-amine


Related News: In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.3-Bromo-5-methylpicolinic acid CAS:1211515-68-2 The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.2-Bromo-1-(4-methylsulfanylphenyl)ethanone Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.3-Glycidoxypropyltrimethoxysilane Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.

Related Products
Product Name
5-(Acetamido)-N,N’-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide Cas:31127-80-7 View Details
TRIS-(4-AMINOPHENYL)THIOPHOSPHATE Cas:52664-35-4 View Details
2,5-Bis(trifluoromethyl)aniline View Details
6-methyluracil manufacturer Antioxidant DHOP manufacturer (R)-1-Boc-3-Aminopiperidine Cas:188111-79-7 manufacturer cyclopirox Olamine Cas:41621-49-2 manufacturer methyl eugenol Cas:93-15-2 manufacturer